Blood Alterations Preceding Clinical Manifestation of Glioblastoma

Author： Ilhan-Mutlu Aysegül   Wagner Ludwig   Wöhrer Adelheid   Jungwirth Susanne   Marosi Christine   Fischer Peter   Preusser Matthias  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.30, Iss.9, 2012-10, pp. : 625-629

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical characteristics and pathogenesis of cerebellar glioblastoma

By              

Molecular Medicine Reports, Vol. 10, Iss. 5, 2014-01 ,pp. : 2383-2388

Spandidos Publications

Access to resources Recommend Favorite

What is the most appropriate clinical target volume for glioblastoma?

By Lo Simon S   Sahgal Arjun   Slotman Ben J   Mansur David B   Khouri Anton   Sloan Andrew E   Machtay Mitchell   Chang Eric L  

CNS Oncology, Vol. 2, Iss. 5, 2013-09 ,pp. : 419-425

Future Medicine

Access to resources Recommend Favorite

Molecular and clinical analysis of glioblastoma with an oligodendroglial component (GBMO)

By Nakamura Hideo  

Brain Tumor Pathology, Vol. 28, Iss. 3, 2011-07 ,pp. : 185-190

Springer Publishing Company

Access to resources Recommend Favorite

Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 11, Iss. 8, 2011-10 ,pp. : 729-738

Bentham Science Publishers

Access to resources Recommend Favorite

miRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients

By            

International Journal of Oncology, Vol. 45, Iss. 2, 2014-01 ,pp. : 746-756

Spandidos Publications

Access to resources Recommend Favorite